Overexpression of calreticulin contributes to the development and progression of pancreatic cancer

Journal of Cellular Physiology

Volumn 229, Issue 7, 2014, Pages 887-897

  Sheng, Weiwei ^a   Chen, Chuanping ^b   Dong, Ming ^a   Zhou, Jianping ^a   Liu, Qingfeng ^c   Dong, Qi ^c   Li, Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The Sixth People s Hospital of Sheyang   (China)

^c People's Hospital of Liaoning Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALRETICULIN; CASPASE 3; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ACINAR CELL; ADULT; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MTT ASSAY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; APOPTOSIS; CALRETICULIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896512867     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24519     Document Type: Article

References (33)

1. Alur M, Nguyen MM, Eggener SE, Jiang F, Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, Michalak M, Dhir R, Wang Z. 2009. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol 175:882-890.
2. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Klöppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC. 1991. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076-1082.
3. Bibi A, Agarwal NK, Dihazi GH, Eltoweissy M, Van Nguyen P, Mueller GA, Dihazi H. 2011. Calreticulin is crucial for calcium homeostasis mediated adaptation and survival of thick ascending limb of Henle's loop cells under osmotic stress. Int J Biochem Cell Biol 43:87-97
4. Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, Cavener D, Diehl JA. 2010. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 29:3881-3895.
5. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. 2010. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2:63ra94.
6. Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM, Ho MC, Hsieh FJ, Lee PH, Kuo ML, Lee H, Chang KJ. 2009. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 16:524-533.
7. Du XL, Yang H, Liu SG, Luo ML, Hao JJ, Zhang Y, Lin DC, Xu X, Cai Y, Zhan QM, Wang MR. 2009. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. Oncogene 28:3714-3722.
8. Erić A, Juranić Z, Milovanović Z, Marković I, Inić M, Stanojević-Bakić N, Vojinović-Golubović V. 2009. Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res 15:89-90.
9. Hayashida Y, Urata Y, Muroi E, Kono T, Miyata Y, Nomata K, Kanetake H, Kondo T, Ihara Y. 2006. Calreticulin represses E-cadherin gene expression in Madin-Darby canine kidney cells via slug. J Biol Chem 281:32469-32484.
10. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD, Hanash SM. 2004. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 64:5504-5510.
11. Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Chen CN, Lai DM, Hsieh LJ, Wang BT, Tsao PN, Lee H, Lin MT, Lai HS, Chen WJ. 2005. Calreticulin expression in neuroblastoma-A novel independent prognostic factor. Ann Oncol 16:314-321.
12. Kageyama K, Ihara Y, Goto S, Urata Y, Toda G, Yano K, Kondo T. 2002. Overexpression of calreticulin modulates protein kinase B/Akt signaling to promote apoptosis during cardiac differentiation of cardiomyoblast H9c2 cells. J Biol Chem 277:19255-19264.
13. Kageyama S, Isono T, Matsuda S, Ushio Y, Satomura S, Terai A, Arai Y, Kawakita M, Okada Y, Yoshiki T. 2009. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int J Urol 16:481-486.
14. Lim S, Chang W, Lee BK, Song H, Hong JH, Lee S, Song BW, Kim HJ, Cha MJ, Jang Y, Chung N, Choi SY, Hwang KC. 2008. Enhanced calreticulin expression promotes calcium-dependent apoptosis in postnatal cardiomyocytes. Mol Cells 25:390-396.
15. Liu R, Gong J, Chen J, Li Q, Song C, Zhang J, Li Y, Liu Z, Dong Y, Chen L, Jin B. 2012. Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother 61:855-864.
16. Lu YC, Chen CN, Wang B, Hsu WM, Chen ST, Chang KJ, Chang CC, Lee H. 2011. Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. Am J Pathol 179:1425-1433.
17. Lwin ZM, Guo C, Salim A, Yip GW, Chew FT, Nan J, Thike AA, Tan PH, Bay BH. 2010. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod Pathol 23:1559-1566.
18. Mesaeli N, Phillipson C. 2004. Impaired p53 expression, function, and nuclear localization in calreticulin-deficient cells. Mol Biol Cell 15:1862-1870.
19. Michael D, Oren M. 2003. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13:49-58.
20. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. 2009. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 417:651-666.
21. Michl P, Gress TM. 2013. Current concepts and novel targets in advanced pancreatic cancer. Gut 62:317-326.
22. Munro AJ, Lain S, Lane DP. 2005. P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 92:434-444.
23. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61.
24. Okunaga T, Urata Y, Goto S, Matsuo T, Mizota S, Tsutsumi K, Nagata I, Kondo T, Ihara Y. 2006. Calreticulin, a molecular chaperone in the endoplasmic reticulum, modulates radiosensitivity of human glioblastoma U251MG cells. Cancer Res 66:8662-8671.
25. Orr AW, Elzie CA, Kucik DF, Murphy-Ullrich JE. 2003. Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. J Cell Sci 116:2917-2927.
26. Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M. 2000. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol 14:999-1009.
27. Prathyuman S, Sellappa S, Joseph S, Keyan KS. 2010. Enhanced calreticulin expression triggers apoptosis in the MCF-7 cell line. Asian Pac J Cancer Prev 11:1133-1136.
28. Sheng W, Dong M, Zhou J, Li X, Liu Q, Dong Q, Li F. 2013a. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer. Cell Tissue Res 354:521-532.
29. Sheng W, Dong M, Zhou J, Li X, Dong Q. 2013b. Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with PC. J Surg Oncol 107:536-543.
30. Shih YY, Nakagawara A, Lee H, Juan HF, Jeng YM, Lin DT, Yang YL, Tsay YG, Huang MC, Pan CY, Hsu WM, Liao YF. 2012. Calreticulin mediates nerve growth factor-induced neuronal differentiation. J Mol Neurosci 47:571-581.
31. Sung CO, Han SY, Kim SH. 2011. Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol 18:273-281.
32. Toquet C, Jarry A, Bou-Hanna C, Bach K, Denis MG, Mosnier JF, Laboisse CL. 2007. Altered calreticulin expression in human colon cancer: Maintenance of calreticulin expression is associated with mucinous differentiation. Oncol Rep 17:1101-1107.
33. Wemeau M, Kepp O, Tesnière A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N. 2010. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 1:e104.